Peroxisome proliferator-activated receptor-γ and -δ Polymorphisms in women with polycystic ovary syndrome

Annals of the New York Academy of Sciences

Volumn 1205, Issue , 2010, Pages 185-191

  Christopoulos, P ^a   Mastorakos, G ^a   Gazouli, M ^a   Deligeoroglou, E ^a   Katsikis, I ^b   Diamanti Kandarakis, E ^c   Panidis, D ^b   Creatsas, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

gene; hormones; PCOS; polymorphism; PPAR ; PPAR

Indexed keywords

GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR THETA; TESTOSTERONE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ADULT; ALLELE; CASE CONTROL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIET RESTRICTION; DISEASE CARRIER; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; RISK; TESTOSTERONE BLOOD LEVEL; VOLUNTEER; ANALYSIS; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; MULTICENTER STUDY; PHYSIOLOGY; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FASTING; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PPAR DELTA; PPAR GAMMA; TESTOSTERONE; YOUNG ADULT;

EID: 77957075052     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05647.x     Document Type: Conference Paper

References (36)

1. Diamanti-Kandarakis, E., C.R. Kouli, A.T. Bergiele, et al.1999.Asurvey of the polycystic ovary syndrome in theGreek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84: 4006-4011.
2. Dunaif, A., D. Scott, D. Finegood, et al. 1996. The insulinsensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81: 3299-3306.
3. Conway, G.S., R. Agrawal, D.J. Betteridge, et al. 1992. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 37: 119-125.
4. Carmina, E. & R.A. Lobo. 1999. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84: 1897-1899.
5. Dunaif, A. 1997. Insulin resistance and the polycystic ovarysyndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18: 774-800.
6. Rocchi, S. & J. Auwerx. 2000. Peroxisome proliferatoractivated receptor gamma, the ultimate liaison between fat and transcription. Br. J. Nutr. 84(Suppl. 2): S223-227.
7. Tamori, Y., J. Masugi, N. Nishino, et al. 2002. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51: 2045-2055.
8. Escobar-Morreale, H.F., M. Luque-Ramirez & J.L. San Millan. 2005. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26: 251-282.
9. Diamanti-Kandarakis, E.&C. Piperi. 2005. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum. Reprod. Update 11: 631-643.
10. Meirhaeghe, A., L. Fajas, N.Helbecque, et al. 1998. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum. Mol. Genet. 7: 435-440.
11. Valve, R., K. Sivenius, R. Miettinen, et al. 1999. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84: 3708-3712.
12. Hara, M., S.Y. Alcoser, A. Qaadir, et al. 2002. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J. Clin. Endocrinol. Metab. 87: 772-775.
13. Skogsberg, J., K. Kannisto, T.N. Cassel, et al. 2003. Evidence that peroxisome proliferators-activated receptor delta influences cholesterol metabolism in man. Arterioscler. Thromb. Vasc. Biol. 23: 637-643.
14. Shin,H.D.,B.L.Park, L.H.Kim,et al. 2004. Geneticpolymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 53: 847-851.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81: 19-25.
16. Dunaif, A. 1999. Insulin action in the polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 28: 341-359.
17. Mastorakos, G., C. Koliopoulos & G. Creatsas. 2002. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril. 77: 919-927.
18. Morley, J.E., P. Patrick & H.M. Perry, III. 2002. Evaluation of assays available to measure free testosterone. Metabolism 51: 554-559.
19. Orio, Jr., F., F. Matarese, S. Di Biase, et al. 2003. Exon 6 and 2 peroxisome proliferators-activated receptor- polymorphisms in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88: 5887-5892.
20. Holte, J. 1996. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin. Endocrinol. Metab. 10: 221-247.
21. Nestler, J.E. 1997. Insulin regulation of human ovarian androgens. Hum. Reprod. 12(Suppl 1): 53-62.
22. Tok, E.C., A. Aktas, D. Ertunc, et al. 2005. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferatoractivated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum. Reprod. 20: 1590-1595.
23. Haap, M., F. Machicao, N. Stefan, et al. 2005. Genetic determinants of insulin action in polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes. 113: 275-281.
24. Wang, Y., X. Wu, Y. Cao, et al. 2006. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil. Steril. 85: 1536-1540.
25. Antoine, H.J., M. Pall, B.C. Trader, et al. 2007. Genetic variants in peroxisome proliferator-activated receptor gammainfluence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil. Steril. 87: 862-869.
26. Korhonen, S., S. Heinonen, M. Hiltunen, et al. 2003. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum. Reprod. 18: 540-543.
27. Yilmaz, M., M.A. Ergu¨n, A. Karakoc¸, et al. 2006. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol. Endocrinol. 22: 336-342.
28. Dedoussis, G.V., E.V. Theodoraki, Y. Manios, et al. 2007. The Pro12Ala polymorphism in PPARgamma2 gene affects lipid parameters in Greek primary school children: a case of gene-to-gender interaction. Am. J. Med. Sci. 333: 10-15.
29. Theodoropoulos, G., I. Papaconstantinou, E. Felekouras, et al. 2006. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J. Gastroenterol. 12: 5037-5043.
30. Azziz, R., D. Ehrmann, R.S. Legro, et al. 2001. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebocontrolled trial. J. Clin. Endocrinol. Metab. 86: 1626-1632.
31. Dereli, D, T. Dereli, F. Bayraktar, et al. 2005. Endocrine and etabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr. J . 52: 299-308.
32. Hasegawa, I., H. Murakawa, M. Suzuki, et al. 1999. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil. Steril. 71: 323-327.
33. Ehrmann,D.A.,D.J. Schneider, B.E. Sobel, et al. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82: 2108-2116.
34. Hu, C.,W. Jia, Q. Fang, et al. 2006. Peroxisome proliferatoractivated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet. Med. 23: 1307-1312.
35. Oliver,W.R. Jr., J.L. Shenk,M.R. Snaith, et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98: 5306-5311.
36. Lee, C.H., P. Olson, A. Hevener, et al. 2006. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 103: 3444-3449.Ann.